Oral lactoferrin for the prevention of sepsis and necrotizing enterocolitis in preterm infants - PubMed (original) (raw)
Review
Oral lactoferrin for the prevention of sepsis and necrotizing enterocolitis in preterm infants
Mohan Pammi et al. Cochrane Database Syst Rev. 2015.
Update in
- Enteral lactoferrin supplementation for prevention of sepsis and necrotizing enterocolitis in preterm infants.
Pammi M, Suresh G. Pammi M, et al. Cochrane Database Syst Rev. 2017 Jun 28;6(6):CD007137. doi: 10.1002/14651858.CD007137.pub5. Cochrane Database Syst Rev. 2017. PMID: 28658720 Free PMC article. Updated. Review.
Abstract
Background: Lactoferrin, a normal component of human colostrum and milk, can enhance host defense and may be effective in the prevention of sepsis and necrotizing enterocolitis (NEC) in preterm neonates.
Objectives: Primary objective To assess the safety and effectiveness of oral lactoferrin in the prevention of sepsis and NEC in preterm neonates. Secondary objectives1. To determine the effects of oral lactoferrin used to prevent neonatal sepsis and/or NEC on duration of positive-pressure ventilation, development of chronic lung disease (CLD) or periventricular leukomalacia (PVL), length of hospital stay to discharge among survivors, and adverse neurological outcomes at two years of age or later.2. To determine the adverse effects of oral lactoferrin in the prophylaxis of neonatal sepsis and/or NEC.When data were available, we analyzed the following subgroups.1. Gestational age < 32 weeks and 32 to 36 weeks.2. Birth weight < 1000 g (extremely low birth weight (ELBW) infants) and birth weight < 1500 g (very low birth weight (VLBW) infants).3. Type of feeding: breast milk versus formula milk.
Search methods: We used the search strategy of the Cochrane Neonatal Review Group (CNRG) and updated our search in July 2014. We searched the databases Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, PREMEDLINE, EMBASE, and the Cumulative Index to Nursing and Allied Health Literature (CINAHL), as well as trials registries and conference proceedings.
Selection criteria: Randomized controlled trials (RCTs) evaluating oral lactoferrin at any dose or duration to prevent sepsis or NEC in preterm neonates.
Data collection and analysis: Review authors used standard methods of the CNRG.
Main results: Four RCTs are included in this review. Oral lactoferrin supplementation decreased late-onset sepsis (typical risk ratio (RR) 0.49, 95% confidence interval (CI) 0.32 to 0.73; typical risk difference (RD) -0.09, 95% CI -0.14 to -0.04; number needed to treat for an additional beneficial outcome (NNTB) 11, 95% CI 7 to 25; four trials, 678 participants, moderate-quality evidence), NEC stage II or greater (typical RR 0.30, 95% CI 0.12 to 0.76; typical RD -0.05, 95% CI -0.08 to -0.01; NNTB 20, 95% CI 12.5 to 100; two studies, 505 participants, low-quality evidence), and "all-cause mortality" (typical RR 0.30, 95% CI 0.12 to 0.75; typical RD -0.05, 95% CI -0.08 to -0.01; NNTB 20, 95% CI 12.5 to 100; two studies, 505 participants, low-quality evidence).Oral lactoferrin supplementation with a probiotic decreased late-onset sepsis (RR 0.27, 95% CI 0.12 to 0.60; RD -0.13, 95% CI -0.19 to -0.06; NNTB 8, 95% CI 5 to 17; one study, 321 participants, low-quality evidence) and NEC stage II or greater (RR 0.04, 95% CI 0.00 to 0.62; RD -0.05, 95% CI -0.08 to -0.03; NNTB 20, 95% CI 12.5 to 33.3; one study, 496 participants, low-quality evidence), but not "all-cause mortality."Oral lactoferrin with or without probiotics decreased fungal sepsis but not chronic lung disease or length of hospital stay (from one study, low-quality evidence). No adverse effects were reported. Long-term neurological outcomes or periventricular leukomalacia was not evaluated.
Authors' conclusions: Evidence of moderate to low quality suggests that oral lactoferrin prophylaxis with or without probiotics decreases late-onset sepsis and NEC stage II or greater in preterm infants without adverse effects. Completion of ongoing trials will provide evidence from more than 6000 preterm neonates and may enhance the quality of the evidence. Clarifications regarding optimum dosing regimens, type of lactoferrin (human or bovine), and long-term outcomes are still needed.
Update of
- Oral lactoferrin for the prevention of sepsis and necrotizing enterocolitis in preterm infants.
Pammi M, Abrams SA. Pammi M, et al. Cochrane Database Syst Rev. 2011 Oct 5;(10):CD007137. doi: 10.1002/14651858.CD007137.pub3. Cochrane Database Syst Rev. 2011. PMID: 21975765 Updated. Review.
Similar articles
- Enteral lactoferrin supplementation for prevention of sepsis and necrotizing enterocolitis in preterm infants.
Pammi M, Suresh G. Pammi M, et al. Cochrane Database Syst Rev. 2020 Mar 31;3(3):CD007137. doi: 10.1002/14651858.CD007137.pub6. Cochrane Database Syst Rev. 2020. PMID: 32232984 Free PMC article. - Enteral lactoferrin supplementation for prevention of sepsis and necrotizing enterocolitis in preterm infants.
Pammi M, Suresh G. Pammi M, et al. Cochrane Database Syst Rev. 2017 Jun 28;6(6):CD007137. doi: 10.1002/14651858.CD007137.pub5. Cochrane Database Syst Rev. 2017. PMID: 28658720 Free PMC article. Updated. Review. - Oral lactoferrin for the prevention of sepsis and necrotizing enterocolitis in preterm infants.
Venkatesh MP, Abrams SA. Venkatesh MP, et al. Cochrane Database Syst Rev. 2010 May 12;(5):CD007137. doi: 10.1002/14651858.CD007137.pub2. Cochrane Database Syst Rev. 2010. PMID: 20464748 Updated. Review. - Oral lactoferrin for the prevention of sepsis and necrotizing enterocolitis in preterm infants.
Pammi M, Abrams SA. Pammi M, et al. Cochrane Database Syst Rev. 2011 Oct 5;(10):CD007137. doi: 10.1002/14651858.CD007137.pub3. Cochrane Database Syst Rev. 2011. PMID: 21975765 Updated. Review. - Inositol in preterm infants at risk for or having respiratory distress syndrome.
Howlett A, Ohlsson A, Plakkal N. Howlett A, et al. Cochrane Database Syst Rev. 2019 Jul 8;7(7):CD000366. doi: 10.1002/14651858.CD000366.pub4. Cochrane Database Syst Rev. 2019. PMID: 31283839 Free PMC article.
Cited by
- Enteral lactoferrin supplementation for prevention of sepsis and necrotizing enterocolitis in preterm infants.
Pammi M, Suresh G. Pammi M, et al. Cochrane Database Syst Rev. 2020 Mar 31;3(3):CD007137. doi: 10.1002/14651858.CD007137.pub6. Cochrane Database Syst Rev. 2020. PMID: 32232984 Free PMC article. - Synergistic Killing of Pathogenic Escherichia coli Using Camel Lactoferrin from Different Saudi Camel Clans and Various Antibiotics.
Almehdar HA, El-Baky NA, Alhaider AA, Almuhaideb SA, Alhaider AA, Albiheyri RS, Uversky VN, Redwan EM. Almehdar HA, et al. Protein J. 2019 Aug;38(4):479-496. doi: 10.1007/s10930-019-09828-5. Protein J. 2019. PMID: 30963371 - The Role of Mucosal Immunity in the Pathogenesis of Necrotizing Enterocolitis.
Hodzic Z, Bolock AM, Good M. Hodzic Z, et al. Front Pediatr. 2017 Mar 3;5:40. doi: 10.3389/fped.2017.00040. eCollection 2017. Front Pediatr. 2017. PMID: 28316967 Free PMC article. Review. - Human Milk: An Ideal Food for Nutrition of Preterm Newborn.
Boquien CY. Boquien CY. Front Pediatr. 2018 Oct 16;6:295. doi: 10.3389/fped.2018.00295. eCollection 2018. Front Pediatr. 2018. PMID: 30386758 Free PMC article. Review. - Human Milk Components Modulate Toll-Like Receptor-Mediated Inflammation.
He Y, Lawlor NT, Newburg DS. He Y, et al. Adv Nutr. 2016 Jan 15;7(1):102-11. doi: 10.3945/an.115.010090. Print 2016 Jan. Adv Nutr. 2016. PMID: 26773018 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous